Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by BioInvent International

BioInvent Moves to NASDAQ Stockholm’s Mid Cap Segment
From BioInvent International
Via AccessWire
BioInvent announces positive early data from ongoing solid cancer trial of BI-1206 in combination with pembrolizumab
From BioInvent International
Via AccessWire
BioInvent’s Latest NHL Data at ASH Show Increased and Sustained Responses to BI-1206 in Relapsed Patients
From BioInvent International
Via AccessWire
BioInvent and CASI Pharmaceuticals Announce CTA Approval for Clinical Studies of BI-1206 in NHL in China
From BioInvent International
Via AccessWire
Tickers CASI
BioInvent has Submitted a CTA for a Phase 1/2a trial of BI-1607, a Novel anti-FcyRIIB Antibody for the Treatment of Patients with Solid Tumors
From BioInvent International
Via AccessWire
Nomination Committee Appointed for BioInvent International’s Annual General Meeting 2022
From BioInvent International
Via AccessWire
BioInvent Hosting Key Opinion Leader Webinar on BI-1206
From BioInvent International
Via AccessWire
BioInvent and Transgene present preclinical data highlighting the robust anti-tumoral activity of BT-001 oncolytic virus at SITC 2021
From BioInvent International
Via AccessWire
Topics Artificial Intelligence
Exposures Artificial Intelligence
BioInvent to Show Further Positive BI-1206 Clinical Data in December at ASH 2021
From BioInvent International
Via AccessWire
Invitation to Presentation of BioInvent’s Interim Report January–September 2021
From BioInvent International
Via AccessWire
BioInvent International AB Interim Report January - September 2021
From BioInvent International
Via AccessWire
BioInvent Appoints Immunotherapy Expert Alexander Eggermont to Scientific Advisory Board
From BioInvent International
Via AccessWire
BioInvent and Transgene to present preclinical data on BT-001 oncolytic virus at SITC 2021
From BioInvent International
Via AccessWire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.